Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

Aberdeen Group plc boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 583,884 shares of the biotechnology company's stock after purchasing an additional 41,018 shares during the quarter. Aberdeen Group

Shares of Vericel Corporation (NASDAQ: VCEL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.

Congress Asset Management Co. grew its holdings in shares of Vericel Corporation (NASDAQ: VCEL) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,664,578 shares of the biotechnology company's stock after purchasing an additional 169,971 shares during the period. Congress Asset Management